Development of an obesity-related multi-gene prognostic model incorporating clinical characteristics in luminal breast cancer

Despite adjuvant chemotherapy and endocrine therapy in luminal breast cancer (LBC), relapses are common. Addressing this, we aim to develop a prognostic model to refine adjuvant therapy strategies, particularly for patients at high recurrence risk. Notably, obesity profoundly affects the tumor micro...

Full description

Saved in:
Bibliographic Details
Published iniScience Vol. 27; no. 3; p. 109133
Main Authors Zhang, Hengjun, Ma, Shuai, Wang, Yusong, Chen, Xiuyun, Li, Yumeng, Wang, Mozhi, Xu, Yingying
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.03.2024
Elsevier
Subjects
Biological sciences
Cancer systems biology
Health sciences
Internal medicine
Medical specialty
Medicine
Natural sciences
Oncology
Systems biology
Medicine
Health sciences
Cancer systems biology
Internal medicine
Natural sciences
Systems biology
Oncology
Biological sciences
Medical specialty
Online AccessGet full text

Cover

More Information
Summary:Despite adjuvant chemotherapy and endocrine therapy in luminal breast cancer (LBC), relapses are common. Addressing this, we aim to develop a prognostic model to refine adjuvant therapy strategies, particularly for patients at high recurrence risk. Notably, obesity profoundly affects the tumor microenvironment (TME) of LBC. However, it is unclear whether obesity-related biological features can effectively screen high-risk patients. Utilizing weighted gene coexpression network analysis (WGCNA) on RNA sequencing (RNAseq) data, we identified seven obese LBC genes (OLGs) closely associated with patient prognosis. Subsequently, we developed a luminal obesity-gene clinical prognostic index (LOG-CPI), combining a 7-gene signature, TNM staging, and age. Its predictive efficacy was confirmed across validation datasets and a clinical cohort (5-year accuracy = 0.828, 0.760, 0.751, and 0.792, respectively). LOG-CPI emerges as a promising predictor for clinical prognosis and treatment response, helping distinguish molecular and immunological features in LBC patients and guiding clinical practice by identifying varying prognoses. [Display omitted] •Obesity modulates LBC TME and impacts patient prognosis•Obesity biological features plus clinicopathology better predict LBC recurrence risk•Exploring molecular and immunological features as key LBC TME regulators Health sciences; Medicine; Medical specialty; Internal medicine; Oncology; Natural sciences; Biological sciences; Systems biology; Cancer systems biology
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally
Lead contact
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2024.109133